ZVSA (ZyVersa Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics 3-Year Dividend Growth Rate?

ZyVersa Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The historical rank and industry rank for ZyVersa Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

ZVSA's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

ZyVersa Therapeutics's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, ZyVersa Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of ZyVersa Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, ZyVersa Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZyVersa Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's 3-Year Dividend Growth Rate falls into.

ZyVersa Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

ZyVersa Therapeutics (NAS:ZVSA) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

ZyVersa Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-2.43
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZyVersa Therapeutics 3-Year Dividend Growth Rate Related Terms>

ZyVersa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326

Website

https://www.zyversa.com

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Executives

Pablo A. Guzman	officer: Chief Medical Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover	director, officer: Chief Executive Officer	108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr.	officer: Chief Scientific Officer	C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe	officer: Chief Financial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere	officer: Chief Commercial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park	director	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd.	10 percent owner	4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones	director, officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor	director, officer: Chief Executive Officer	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp.	10 percent owner	88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880